This page contains information about funding opportunities with Industry. If you are thinking of applying, please read all terms and conditions and feel free to get in touch with the named Oxford contact to talk more about the opportunity.
The Medical and Life Sciences Translational Fund (MLSTF) is open to all University of Oxford researchers and provides consolidated internal proof of concept funding for translational medical and life sciences projects.
The next round opens on Thursday 16 March 2023.
Pfizer is seeking proposals for renal disease target discovery utilising functional genomics technologies.
Submissions invited for novel functional genomics-driven target discovery efforts in renal disease, making use of highly relevant model systems and informative, high-dimensional readouts:
- Ex vivo tissue
- Microphysiological systems
- Primary cells
- Complex cell mixtures
- Other innovative and highly relevant model systems
- High-dimensional readouts that capture disease biology
- Single-cell approaches
- Transcriptomics and proteomics
- High-content imaging assays
- Gene editing and other functional genomics methods
- Functional genomics screening approaches at medium to large-scale
- Chronic kidney disease
- Diabetic nephropathy
- Glomerular/tubular biology
- Polycystic kidney disease
Out of scope
- Rare kidney disease
- Alport syndrome
- Focal segmental glomerulosclerosis
- IgA nephropathy
Submission deadline: 21 April 2023
For more information, please contact Nicole Le Grand, Business Partnerships Manager, Business Partnerships Office at email@example.com.
Seeking Novel Leads in Rare Diseases and Neuroscience
Ipsen, a global biopharmaceutical company, is seeking novel and innovative leads to treat rare disease and rare neuroscience disease indications. A range of therapeutic areas and targets will be considered, but target diseases should be rare (>1.5 per million, <1 per 2,000).
A range of mechanisms‑of‑action and classes of molecules are of interest, with a particular focus on small molecules, peptides, biologics, nucleic acids, RNA therapies (i.e. siRNAs) and antibody conjugates. Ipsen is open to a variety of drug delivery methods.
Development Stage of Interest
Approaches of interest are preferred to be clinical‑stage assets at pre‑IND, clinical phase I or clinical phase II. Research should be validated empirically, e.g. through in vitro animal proof of concept studies.
Target Clinical Indications
The main areas of focus can be related to: endocrinology, hepatic disease, inborn errors of metabolism, neuromuscular disease and musculoskeletal disease.
Out of Scope
Ultra‑rare diseases (<1.5 per million)
Assets that treat rare dermatology, pulmonary, haematology, ophthalmology and infectious indications only Neurological diseases such as Alzheimer’s, Parkinson’s, multiple sclerosis, general pain and psychiatry
Gene therapy, cell therapy, stem cell/regenerative therapies, vaccines, biosimilars/generic, traditional or herbal medicine, natural products, and medical devices
Research‑stage assets (unless clinic‑ready or with empirical validation)
Submission of one-page, 200-300 word briefs are encouraged, along with any optional supplementary information e.g. relevant publications. Intellectual property status of the research should be included where relevant. Applicants are encouraged to ﬁll in an application form to provide more in-depth information alongside their submission to this campaign. In submitting to this campaign, you conﬁrm that your submission contains only non-conﬁdential information.
Ipsen are seeking a variety of collaboration opportunities including asset acquisition and partnering, to be decided on a case- by-case basis.
Deadline: Monday 24 April 2023 – 10.59 pm GMT
For an application form, a full list of diseases of interest, and assistance on submissions, please contact Denitsa Filipova in the Business Partnerships Office (firstname.lastname@example.org).
The Novartis Institutes for BioMedical Research (NIBR) is seeking to advance science through their Global Scholars Program. The funding of up to $1 million over a 3-year period and is open to Principal Investigators. The University of Oxford has been selected by Novartis as a partner for their scholars program.
Read more about the NIBR Global Scholars Program and apply (Oxford single-sign on required)